Dermatology Times

🌟 Welcome to this week's edition of Dermatology Times' LinkedIn newsletter! As November wraps up, we're reflecting on a month rich with advancements in dermatology. Review insights from the month in this Skin-Sights: Month in Review edition. ⬇️ 👥📲 Join our community of more than 11,300 (and counting!) dermatology and industry professionals receiving curated skin news every week by subscribing to our newsletter today.

📊👥 CALL FOR INSIGHTS: As we approach the final month of the year, Dermatology Times is gearing up to craft a guide to 2025's dermatologic conferences and meetings. Please email us at DTEditor@mmhgroup.com by December 10, detailing the conferences and meetings you plan to attend in the first quarter of 2025. https://lnkd.in/gFHVTx3c

🗓️ IN REVIEW: Our November Case-Based Peer Perspective supplement includes a collection of thought-provoking discussions and strategies surrounding tips for improving complex atopic dermatitis and vitiligo treatments from Terry Faleye, MPAS, PA-C, Andrea Rosik, MS, PA-C; and Jayme Heim, MSN, FNP-BC. Be sure to read the highlights from the supplement below. ⬇️ https://lnkd.in/gpMBBTYT

💡 EXPERT INSIGHTS: Jason Hawkes, MD, MS, discusses the growing overlap between oncology and dermatology, particularly regarding the effects of immune checkpoint inhibitors. In a session at the Elevate-Derm West conference, Hawkes and James Song, MD, FAAD, explored the mechanisms, challenges, and management of dermatological toxicities associated with these groundbreaking cancer therapies. 🎥 View the full interview now: https://lnkd.in/gqghefBn

📰 FROM OUR PUBLICATION: The November Chronic Hand Eczema supplement of Dermatology Times includes a collection of thought-provoking articles and topics ranging from the psychosocial and socioeconomic burdens of CHE to the results of LEO Pharma’s multinational CHECK study. Don’t miss a moment of Dermatology Times by signing up for our eNewsletters and subscribing to receive the free print issue and supplement each month: https://lnkd.in/d9HJJzcV https://lnkd.in/grz25QBj

📚 STUDY FINDINGS: Galderma recently announced that data from its phase 3 OLYMPIA 1 trial was published in JAMA Dermatology. The data demonstrated the efficacy of #nemolizumab in treating adults with moderate to severe prurigo nodularis. At week 16, significantly more patients receiving treatment with nemolizumab demonstrated improvement in both itch severity and skin lesions compared to the placebo group. Read more: https://lnkd.in/g-UEh2j5

👥 UPCOMING CONFERENCES: Dermatology Times asked our readers to share with us what conferences and meetings they are looking forward to or planning to attend in the fourth quarter of the year. Read more below about what conferences to attend and email DTEditor@mmhgroup.com to share your insights. https://lnkd.in/gE7yqXFn

📰 FROM OUR PUBLICATION: The November issue of Dermatology Times includes a collection of thought-provoking articles and topics ranging from the role of artificial intelligence in developing zasocitinib, to the clinical considerations in treating pediatric melanoma. Don’t miss a moment of Dermatology Times by signing up for our eNewsletters and subscribing to receive the free print issue and supplement each month: https://lnkd.in/d9HJJzcV https://lnkd.in/gFw7nqf6

📈 NEW DATA: A recent study revealed the high efficacy and safety of combining radiofrequency microneedling with Cysteamine cream to treat refractory melasma. Previous clinical trials have confirmed Cysteamine’s power to diminish melasma within 8 to 16 weeks. However, this is the first study to assess the combined approach of RFM and cysteamine. 🔗 Read more: https://lnkd.in/gdWM_pf3

How can diversity in dermatology research drive better patient care? Learn more about Johnson & Johnson's initiatives to address health care disparities. #ad Read more: https://ow.ly/amhe50UgVSU